



Tiered Biologics Reimbursement Policy Flowsheet

New Patients (Biologic-Naïve):



Existing Patients:



*NOTE: Patients will not be permitted to switch from *Abrilada, Amgevita, Avsola, Brenzys, Erelzi, Hadlima, Hulio, Hyrimoz, Idacio, Inflectra, Renflexis, Riabni, Riximyo, Ruxience, Truxima, *Simlandi, or *Yuflyma to another adalimumab, etanercept, infliximab or rituximab product listed in Tier 1 and/or Tier 2 if previously trialed and deemed unresponsive to therapy.*

NOTE: Patients will not be permitted to switch from Remicade, Enbrel, Humira or Rituxan to another infliximab, etanercept, adalimumab or rituximab product listed in Tier 1 if previously trialed and deemed unresponsive to therapy.